ERBB2 and neoplasm: However, mutation profiling with next-generation DNA sequencing and RNA sequencing (Tempus, Chicago, IL) on tumor tissue confirmed continued high-copy HER2 amplification (>20 copies) and HER2 mRNA overexpression (99.7+% rank) among the Tempus PDAC database.